The Oncopole would like to congratulate the 56 teams invited to submit a full application to the Oncopole EMC2 competition. We are very pleased by the great interest for this first call for proposals proving the dynamism of oncology research in Québec.

We invite you to consult the list.

Since interdisciplinary and multi-institutional work is one of the objectives of the competition, projects’ and team consolidation is encouraged.

For more details on the competition: oncopole.ca/oncopole-emc2-first-call-for-proposals-on-the-oncopole?lang=en

Call for proposals              

Oncopole EMC2: Équipes multi-institutionnelles contre le cancer
(multi-institutional teams against cancer)             

The Oncopole, in partnership with the FRQS, is pleased to announce the launch of its first Call for proposals. This competition aims to support collaborative and structuring research projects that will build on Québec’s expertise and strengths in oncology.

By fostering collaboration between disciplines and institutions, the Oncopole wants to support the mobilization of Québec’s key players in order to tackle the public health challenge that cancer represents.

The power of collaboration

The teams must be interdisciplinary and made up of investigators from at least three institutions, research centers and institutes, or departments affiliated to a minimum of two Québec universities. The team may be composed of a maximum of three Principal Investigators and a minimum of four co-Investigators.

Research areas

Interdisciplinary research projects may focus on prevention, diagnosis or treatment, and be at the discovery stage, translational or preclinical research, early clinical research or evaluative research. Clinical trials that would normally only be funded by the industry are not eligible.

The program is open to all types of cancer. Projects must clearly align with a clinical need.

Program budget: $6M

Amount of the grant: maximum of $1.5M over 3 years. Co-funding is not mandatory.

Important dates

Deadline for submitting the notice of intent: November 24, 2017, 4:30 pm

Deadline for submitting the complete application: February 19, 2018, 4:30 pm

To access the program rules click here.

For more information on the proposal, please contact Manon Pelletier, Program Manager at FRQS.

For more information about the Oncopole, please contact Maxime Dumais, Program Manager at Oncopole

N.B.  Conference call information sessions about this Program will be held on October 30 (in French) and November 1 (in English).

Conference call: 514-736-8030 or 1-866-500-7802, access #: 1362430

PowerPoint presentation access:

                                                                               

Montréal, May 8, 2017- The Oncopole, a research, development and investment hub designed to accelerate the fight against cancer, announced today the appointment of Ms. Stéphanie Lord-Fontaine as Executive Director of the organization.

Launched in February 2017 through a co-creation partnership of the Fonds de recherche du Québec – Santé (FRQS) and Merck & Co, inc., the Oncopole brings together different partners of the life sciences field to collaborate on a structuring project to fight cancer, strengthening as a result our research and innovation ecosystem, including the resources, infrastructures and researchers here in Quebec, to the patient’s benefit. The Oncopole benefits from a 15‑million dollar funding commitment over three year from Merck and looks forward to welcoming the contribution of other partners.

Initiators of this forward-looking project, the FRQS and Merck are delighted by the nomination of Ms. Lord-Fontaine as Executive Director. Following Friday’s announcement, Oncopole’s partners welcome the Quebec Life Sciences Strategy and are confident that Ms. Lord-Fontaine will seize the opportunity it represents. She will work to put forward the Oncopole’s four priorities: research, entrepreneurship and promotion of innovation, integration of innovation and clinical relevance, training and awareness.

Ms. Lord-Fontaine has more than 15 years of experience in the academic and biopharmaceutical sectors as well as in the field of research funding agencies. Prior to accepting the Executive Director position at the Oncopole, Ms. Lord-Fontaine was Senior Director, Scientific Affairs at Génome Québec and Director, Preclinical research at BioAxone Therapeutic. She holds a PhD in biochemistry and continued with a Post-Doctorate degree in neuroscience.

Ms. Lord-Fontaine will be able to rely on the operational support of the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal which was selected as the establishment to host the Oncopole’s coordinating offices.

About the Fonds de recherche du Québec – Santé

The mission of the Fonds de recherche du Québec – Santé (FRQS) is to support research in the field of health to promote the well-being of the population of Québec. It was given the mandate of promoting and providing financial support for research in this field, for the dissemination of scientific knowledge as well as researcher training, for the creation of any partnership essential to the development of Québec’s innovation and research system, and, finally, to stimulate research influence around the world. The FQRS reports to the Minister of Economy, Science and Innovation. http://www.frqs.gouv.qc.ca/en/accueil

About Merck

For over a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information about our operations in Canada, visit www.merck.ca and connect with us on YouTube and Twitter @MerckCanada.

About the Institute for Research in Immunology and Cancer

An ultra-modern research hub and training centre located in the heart of the Université de Montréal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. The IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer.

For more information: www.iric.ca/en/

QUÉBEC CITY – Merck Canada is partnering with the FRQS to create the « Oncopole », a new research, development and investment hub designed to accelerate, on all fronts, the fight against cancer. This innovative and structuring project is moving forward on solid footing thanks to a 15-million dollar funding commitment over three years from Merck.

Unveiled on February 15, 2017 in Québec City with several Québec government, FRQS and Merck Canada representatives in attendance, the Oncopole is designed to bring all stakeholders and actors involved in the fight against cancer together around common strategic objectives, putting patients at the heart of its actions. In the past year, over 50 experts have been working together towards the implementation of the organisation whose operating budget will be entirely managed by the FRQS.

MONTREAL – The management team of the Oncopole, has confirmed that its coordinating offices will be located alongside those of the Université de Montréal’s IRIC. Following the organisation’s management and partners thorough analysis, this choice is a logical option that will provide the opportunity to benefit from the expertise and state-of-the-art oncology resources already present at the IRIC. In doing this, it will maximize the existing efforts and initiatives associated with the fight against cancer throughout Québec.